Last updated: 22 August 2022 at 5:28pm EST

Thomas W. Dubensky Net Worth




The estimated Net Worth of Thomas W. Dubensky is at least $928 mil dollars as of 10 August 2017. Thomas Dubensky owns over 50,000 units of HTG Molecular Diagnostics Inc stock worth over $23,514 and over the last 9 years Thomas sold HTGM stock worth over $904,499.

Thomas Dubensky HTGM stock SEC Form 4 insiders trading

Thomas has made over 25 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas exercised 50,000 units of HTGM stock worth $50,000 on 10 August 2017.

The largest trade Thomas's ever made was exercising 144,301 units of HTG Molecular Diagnostics Inc stock on 1 June 2017 worth over $75,037. On average, Thomas trades about 21,420 units every 19 days since 2015. As of 10 August 2017 Thomas still owns at least 48,988 units of HTG Molecular Diagnostics Inc stock.

You can see the complete history of Thomas Dubensky stock trades at the bottom of the page.



What's Thomas Dubensky's mailing address?

Thomas's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSCON, AZ, 85706.

Insiders trading at HTG Molecular Diagnostics Inc

Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, eLaurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.



What does HTG Molecular Diagnostics Inc do?

about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.



Complete history of Thomas Dubensky stock trades at Aduro BioTech e HTG Molecular Diagnostics Inc

Acionista maioritário
Trans.
Transação
Preço total
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $50,000
10 Aug 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $26,000
3 Jul 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $75,037
1 Jun 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $2,963
11 May 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $19,500
9 Mar 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $19,500
9 Mar 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $13,000
3 Jan 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $13,000
3 Jan 2017
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $26,000
1 Dec 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $26,000
1 Dec 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $32,500
10 Nov 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $32,500
10 Nov 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $27,500
3 Oct 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $27,500
3 Oct 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $28,250
1 Sep 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $28,250
1 Sep 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $24,750
11 Aug 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $24,750
11 Aug 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $26,000
5 Jul 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $26,000
5 Jul 2016
Thomas W. Dubensky
Chief Scientific Officer
Venda $7,421
16 May 2016
Thomas W. Dubensky
Chief Scientific Officer
Venda $7,421
16 May 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $70,200
4 Jan 2016
Thomas W. Dubensky
Chief Scientific Officer
Exercício de opção $64,500
1 Dec 2015
Thomas W. Dubensky
Chief Scientific Officer
Venda $889,657
16 Nov 2015


HTG Molecular Diagnostics Inc executives and stock owners

HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include: